Has Christine Barbato received payments from drug or device companies?

Yes. Drug and device makers reported $4,997 in general payments to Christine Barbato across 208 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Christine Barbato did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Christine Barbato come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Christine Barbato

Psychiatric/Mental Health · West Palm Beach, FLNPI 1124647789

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.0% of the total across 208 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 15 manufacturers, the largest accounting for just 23.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $2,066 and has fallen 83.2% since, to $347 in 2025. Among psychiatric/mental health clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$4,997in general payments, 2019–2025

Across 208 payments — averaging $24.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AbbVie$1K
Johnson & Johnson$1K
Alkermes, Inc.$732
Neurocrine Biosciences, Inc.$587
Teva Pharmaceuticals USA, Inc.$574
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$344
plus $507 from 9 others

What the payments were for

Food & beverage$4,94899%
Education$491%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AbbVie	57	$1,147
Johnson & Johnson	36	$1,105
Alkermes, Inc.	27	$732
Neurocrine Biosciences, Inc.	27	$587
Teva Pharmaceuticals USA, Inc.	28	$574
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)	7	$344
Takeda Pharmaceuticals U.S.A., Inc.	15	$193
Biogen	1	$101
Otsuka America Pharmaceutical, Inc.	2	$43
Collegium Pharmaceutical, Inc.	2	$42
Lundbeck LLC	2	$38
Vanda Pharmaceuticals Inc.	1	$30
Corium, LLC	1	$23
Indivior Inc.	1	$22
Bausch Health US, LLC	1	$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,997 in reported general payments places this provider in the 90th percentile of 3,096 psychiatric/mental health providers in Florida.

See all psychiatric/mental health providers in Florida →

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
IngrezzaValbenazine Tosylate	32	$245,839
Invega SustennaPaliperidone Palmitate	60	$213,914
VraylarCariprazine Hcl	72	$100,413
AristadaAripiprazole Lauroxil	14	$49,287
CaplytaLumateperone Tosylate	14	$22,888
Chlorpromazine Hcl	19	$8,892
Clozapine	59	$3,452
Haloperidol Decanoate	63	$3,289
Fluphenazine Decanoate	20	$2,753
Divalproex Sodium	123	$1,812
Olanzapine	124	$1,680
Haloperidol	32	$1,599
Paliperidone ErPaliperidone	13	$1,180
Naltrexone Hcl	33	$1,157
Benztropine Mesylate	127	$1,026

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza	$587	$245,83932 claims
Johnson & JohnsonInvega Sustenna	$1,105	$213,91460 claims
AbbVieVraylar	$1,147	$100,41372 claims
Alkermes, Inc.Aristada	$732	$49,28714 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta	$344	$22,88814 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,096 psychiatric/mental health providers in Florida.

Other psychiatric/mental health in West Palm Beach

Jessica ShepleyWest Palm Beach$14K
Roger RiveraKissimmee$1.6M
Bethanie Simmons BecilJacksonville$782K
Hannah PhillipsMaitland$455K
Scott DurrancePensacola$224K
Eudaldo AponteHialeah$214K
Heather WarrenTallahassee$172K
Angela DavenportAlachua$83K
Natalie MoodyWinter Haven$75K
Kelli BridgmanNew Smyrna Beach$66K

See the full list for Florida →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →